LSKL, Inhibitor of Thrombospondin TSP-1 是一种竞争性的TGF-β1拮抗剂，是一种衍生自 LAP-TGFβ 的四肽。它能够抑制TSP-1介导的TGF-β1活性来抑制蛛网膜下纤维化，防止慢性脑积水的发生并改善蛛网膜下腔出血后的长期神经认知缺陷。

LSKL, Inhibitor of Thrombospondin (TSP-1) is a peptide derived from the latency-associated peptide, inhibits thrombospondin (TSP-1) activation of TGF-β.

The protective effects of the LSKL peptide were achieved via the inhibition of TGF-β1 activity and subsequent Smad2/3 signaling.?The LSKL peptide may improve long-term neurocognitive deficits after SAH.?The LSKL peptide suppresses subarachnoid fibrosis via inhibition of TSP1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following SAH[1].Administration of LSKL peptide attenuated Smad2 phosphorylation at 6 h. S-phase entry of hepatocytes was accelerated at 24 and 48 h by LSKL peptide, which resulted in faster recovery of the residual liver and bodyweight[2].

Mice were operated on with a 70 per cent hepatectomy or sham procedure. Operated mice received either LSKL peptide or normal saline intraperitoneally at abdominal closure and 6 h after hepatectomy. Perioperative plasma TSP-1 levels were measured by enzyme-linked immunosorbent assay in patients undergoing hepatectomy[2].

283609-79-0

C21H42N6O5

458.6

LSKL, Inhibitor of Thrombospondin TSP-1;LSKL, 血小板反应蛋白抑制剂 (TSP-1)

DMSO:100 mg/mL (218.05 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years